Loss of SMURF2 expression enhances RACK1 stability and promotes ovarian cancer progressionYanan Pi(Harbin Medical University), Ge Lou(Harbin Medical University)Cell Death and DifferentiationOctober 12, 202310.1038/s41418-023-01226-wCited by 34SaveCiteExport RISWatch citationsRelated PapersFigure S1-S4, Table S1-S7 from An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline <i>BRCA1/2</i> Mutation and Platinum-sensitive Recurrent Ovarian Cancer|Unknown|2023|0Supplementary Figure from Pamiparib Monotherapy for Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study|Unknown|2023|0Supplementary Data from Pamiparib Monotherapy for Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study|Unknown|2023|0Supplementary Figure from Pamiparib Monotherapy for Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study|Unknown|2023|0Supplementary Figure from Pamiparib Monotherapy for Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study|Unknown|2023|0